Gensight Biologics

This study followed 62 people for five years after they received an experimental gene therapy for a rare genetic eye disease called LHON. The goal was to check the long-term safety of the treatment and see if the vision improvements seen in earlier studies were maintained over ti…

This early-stage trial tested a new gene therapy called GS010 for Leber Hereditary Optic Neuropathy (LHON), a rare genetic condition that causes vision loss. The main goal was to check if the treatment was safe and tolerable for patients. Researchers gave the therapy to 19 adults…

This Phase 3 trial tested whether a single gene therapy injection (GS010) into the eye could improve vision in people with Leber Hereditary Optic Neuropathy (LHON), a rare genetic condition that causes rapid vision loss. The study involved 37 participants who had experienced visi…

This study tested whether a single gene therapy injection (called GS010) into the eye could improve or preserve vision in people with a rare, rapidly progressing form of inherited blindness (LHON). It involved 39 participants who had started losing vision within the last 6 months…

This study aimed to better understand the progression of Leber Hereditary Optic Neuropathy (LHON), a rare genetic condition that causes sudden vision loss. Researchers collected past medical records and surveyed 44 patients to track how their vision changed over time and how the …